http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 16:21:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Maraldo+David+R./26891379.html si-local-file:///var/storage/secattach/20260807/26891379.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Maraldo+David+R./26891379.html Fri, 07 Aug 2026 16:21:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Maraldo+David+R./26891379.html si-local-file:///var/storage/secattach/20260807/26891379.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Maraldo+David+R./26891379.html Fri, 07 Aug 2026 16:21:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Williams+David+Michael/26891344.html si-local-file:///var/storage/secattach/20260807/26891344.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Williams+David+Michael/26891344.html Fri, 07 Aug 2026 16:19:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Williams+David+Michael/26891344.html si-local-file:///var/storage/secattach/20260807/26891344.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+05++Filed+by%3A+Williams+David+Michael/26891344.html Fri, 07 Aug 2026 16:19:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+06++Filed+by%3A+Guindo+Chirfi/26891303.html si-local-file:///var/storage/secattach/20260807/26891303.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+06++Filed+by%3A+Guindo+Chirfi/26891303.html Fri, 07 Aug 2026 16:17:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+06++Filed+by%3A+Guindo+Chirfi/26891303.html si-local-file:///var/storage/secattach/20260807/26891303.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Aug+06++Filed+by%3A+Guindo+Chirfi/26891303.html Fri, 07 Aug 2026 16:17:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26891156.html si-local-file:///var/storage/secattach/20260807/26891156.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26891156.html Fri, 07 Aug 2026 16:12:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26891156.html si-local-file:///var/storage/secattach/20260807/26891156.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26891156.html Fri, 07 Aug 2026 16:12:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26890915.html si-local-file:///var/storage/secattach/20260807/26890915.html http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26890915.html Fri, 07 Aug 2026 16:04:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26890915.html si-local-file:///var/storage/secattach/20260807/26890915.html http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++Merck+%26amp%3B+Co.%2C+Inc.+++++For%3A+Jun+30/26890915.html Fri, 07 Aug 2026 16:04:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+Guindo+Chirfi/26885084.html si-local-file:///var/storage/secattach/20260806/26885084.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+Guindo+Chirfi/26885084.html Thu, 06 Aug 2026 16:47:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+Guindo+Chirfi/26885084.html si-local-file:///var/storage/secattach/20260806/26885084.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+Guindo+Chirfi/26885084.html Thu, 06 Aug 2026 16:47:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+DeLuca+Richard+R./26885049.html si-local-file:///var/storage/secattach/20260806/26885049.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+DeLuca+Richard+R./26885049.html Thu, 06 Aug 2026 16:45:00 -0400 MRK O.00037438 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+DeLuca+Richard+R./26885049.html si-local-file:///var/storage/secattach/20260806/26885049.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Merck+%26amp%3B+Co.%2C+Inc.++++++++++++++++++Filed+by%3A+DeLuca+Richard+R./26885049.html Thu, 06 Aug 2026 16:45:00 -0400 MRK O.00037438 http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html <p>Trump Administration Weighs Order On Autism And Vaccines - Bloomberg</p> http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html Thu, 06 Aug 2026 16:36:01 -0400 GSK MRK MRNA PFE SAN http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html <p>Trump Administration Weighs Order On Autism And Vaccines - Bloomberg</p> http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html Thu, 06 Aug 2026 16:36:01 -0400 GSK MRK MRNA PFE SAN http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html <p>Trump Administration Weighs Order On Autism And Vaccines - Bloomberg</p> http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html Thu, 06 Aug 2026 16:36:01 -0400 GSK MRK MRNA PFE SAN http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html <p>Trump Administration Weighs Order On Autism And Vaccines - Bloomberg</p> http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html Thu, 06 Aug 2026 16:36:01 -0400 GSK MRK MRNA PFE SAN http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html <p>Trump Administration Weighs Order On Autism And Vaccines - Bloomberg</p> http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html Thu, 06 Aug 2026 16:36:01 -0400 GSK MRK MRNA PFE SAN http://www.streetinsider.com/Corporate+News/FDA+accepts+Merck%27s+sBLA+for+Enflonsia+to+cover+second+RSV+season/26878038.html <p>Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration has accepted a supplemental Biologics License Application for Enflonsia (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus lower respiratory tract disease in children under two years of age at increased risk for severe RSV disease through their second RSV season.</p><p>The FDA has set a Prescription Drug User Fee Act target action date of March 22, 2027.</p><p>The European Medicines Agency also accepted an application in July 2026 to expand the marketing authorization for Enflonsia in the European Union for the same patient population.</p><p>Both applications are supported http://www.streetinsider.com/Corporate+News/FDA+accepts+Merck%27s+sBLA+for+Enflonsia+to+cover+second+RSV+season/26878038.html Thu, 06 Aug 2026 06:45:45 -0400 MRK http://www.streetinsider.com/FDA/FDA+accepts+Merck%27s+sBLA+for+Enflonsia+to+cover+second+RSV+season/26878038.html <p>Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration has accepted a supplemental Biologics License Application for Enflonsia (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus lower respiratory tract disease in children under two years of age at increased risk for severe RSV disease through their second RSV season.</p><p>The FDA has set a Prescription Drug User Fee Act target action date of March 22, 2027.</p><p>The European Medicines Agency also accepted an application in July 2026 to expand the marketing authorization for Enflonsia in the European Union for the same patient population.</p><p>Both applications are supported http://www.streetinsider.com/FDA/FDA+accepts+Merck%27s+sBLA+for+Enflonsia+to+cover+second+RSV+season/26878038.html Thu, 06 Aug 2026 06:45:45 -0400 MRK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html <p class="bwalignc"> <b>EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial</b> </p><p class="bwalignc"> <b>If approved, children under two years of age at increased risk for severe RSV disease will be eligible to receive an additional dose of ENFLONSIA for their second RSV season</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html Thu, 06 Aug 2026 06:45:00 -0400 A.06822034 A.31066700 A.60012004 MRK O.00037438 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html <p class="bwalignc"> <b>EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial</b> </p><p class="bwalignc"> <b>If approved, children under two years of age at increased risk for severe RSV disease will be eligible to receive an additional dose of ENFLONSIA for their second RSV season</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html Thu, 06 Aug 2026 06:45:00 -0400 A.06822034 A.31066700 A.60012004 MRK O.00037438 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html <p class="bwalignc"> <b>EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial</b> </p><p class="bwalignc"> <b>If approved, children under two years of age at increased risk for severe RSV disease will be eligible to receive an additional dose of ENFLONSIA for their second RSV season</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html Thu, 06 Aug 2026 06:45:00 -0400 A.06822034 A.31066700 A.60012004 MRK O.00037438 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html <p class="bwalignc"> <b>EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial</b> </p><p class="bwalignc"> <b>If approved, children under two years of age at increased risk for severe RSV disease will be eligible to receive an additional dose of ENFLONSIA for their second RSV season</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+sBLA+for+ENFLONSIA%E2%84%A2+%28clesrovimab-cfor%29+to+Update+its+Respiratory+Syncytial+Virus+%28RSV%29+Lower+Respiratory+Tract+Disease+Indication+to+Include+Children+Under+Two+Years+at+Increased+Ri/26878025.html Thu, 06 Aug 2026 06:45:00 -0400 A.06822034 A.31066700 A.60012004 MRK O.00037438 O.01304637 O.20026344 O.22422661